{"quote": {"result": [{"language": "en-US", "region": "US", "quoteType": "EQUITY", "typeDisp": "Equity", "triggerable": false, "customPriceAlertConfidence": "LOW", "currency": "USD", "exchange": "PNK", "shortName": "PhaseBio Pharmaceuticals, Inc.", "longName": "PhaseBio Pharmaceuticals, Inc.", "messageBoardId": "finmb_3564616", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "marketState": "REGULAR", "regularMarketChangePercent": 0.0, "regularMarketPrice": 0.0007, "regularMarketChange": 0.0, "regularMarketTime": 1684160160, "firstTradeDateMilliseconds": 1539869400000, "priceHint": 4, "regularMarketDayHigh": 0.0007, "regularMarketDayRange": "7.0E-4 - 7.0E-4", "regularMarketDayLow": 0.0007, "regularMarketVolume": 2568, "regularMarketPreviousClose": 0.0007, "fullExchangeName": "Other OTC", "financialCurrency": "USD", "regularMarketOpen": 0.0007, "averageDailyVolume3Month": 44406, "averageDailyVolume10Day": 191532, "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "fiftyTwoWeekLowChange": 0.00039999996, "fiftyTwoWeekLowChangePercent": 1.3333331, "fiftyTwoWeekRange": "3.0E-4 - 1.38", "fiftyTwoWeekHighChange": -1.3793, "fiftyTwoWeekHighChangePercent": -0.99949276, "fiftyTwoWeekLow": 0.0003, "fiftyTwoWeekHigh": 1.38, "earningsTimestamp": 1660307400, "earningsTimestampStart": 1684234740, "earningsTimestampEnd": 1685102400, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "epsTrailingTwelveMonths": -2.45, "epsForward": -1.73, "epsCurrentYear": -1.08, "priceEpsCurrentYear": -0.0006481481, "sharesOutstanding": 49858100, "bookValue": -2.355, "fiftyDayAverage": 0.001038, "fiftyDayAverageChange": -0.000338, "fiftyDayAverageChangePercent": -0.32562622, "twoHundredDayAverage": 0.238379, "twoHundredDayAverageChange": -0.237679, "twoHundredDayAverageChangePercent": -0.9970635, "marketCap": 34900, "forwardPE": -0.00040462427, "priceToBook": -0.0002972399, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "3.0 - Hold", "tradeable": false, "cryptoTradeable": false, "displayName": "PhaseBio Pharmaceuticals", "symbol": "PHASQ"}], "error": null}, "summary": {"result": [{"assetProfile": {"address1": "1 Great Valley Parkway", "address2": "Suite 30", "city": "Malvern", "state": "PA", "zip": "19355", "country": "United States", "phone": "610 981 6500", "fax": "610 981 6520", "website": "https://phasebio.com", "industry": "Biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiovascular diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or an invasive procedure. The company is also developing PB1046, a vasoactive intestinal peptide analogue for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania. On October 23, 2022, PhaseBio Pharmaceuticals, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.", "fullTimeEmployees": 60, "companyOfficers": [{"maxAge": 1, "name": "Mr. Jonathan P. Mow MBA", "age": 57, "title": "Pres, CEO & Director", "yearBorn": 1965, "fiscalYear": 2021, "totalPay": {"raw": 894664, "fmt": "894.66k", "longFmt": "894,664"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 301595, "fmt": "301.6k", "longFmt": "301,595"}}, {"maxAge": 1, "name": "Dr. John S. Lee M.D., Ph.D.", "age": 54, "title": "Chief Medical Officer", "yearBorn": 1968, "fiscalYear": 2021, "totalPay": {"raw": 648884, "fmt": "648.88k", "longFmt": "648,884"}, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 148022, "fmt": "148.02k", "longFmt": "148,022"}}, {"maxAge": 1, "name": "Mr. Lawrence R. Perkins", "age": 45, "title": "Chief Restructuring Officer & Principal Financial Officer", "yearBorn": 1977, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Susan Elizabeth Arnold Ph.D.", "age": 47, "title": "Sr. VP of Technical Operations", "yearBorn": 1975, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Kristopher L. Hanson", "age": 50, "title": "SVP, Gen. Counsel & Corp. Sec.", "yearBorn": 1972, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Glen G. Burkhardt", "age": 63, "title": "Sr. VP of HR", "yearBorn": 1959, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Ms. Lauren  Richardson", "title": "Global Head of Regulatory Affairs & Quality Assurance", "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}, {"maxAge": 1, "name": "Mr. Jonathan J. Birchall", "age": 53, "title": "Chief Commercial Officer", "yearBorn": 1969, "exercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}, "unexercisedValue": {"raw": 0, "fmt": null, "longFmt": "0"}}], "compensationAsOfEpochDate": 1640908800, "maxAge": 86400}}], "error": null}}